Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pivekimab sunirine by ImmunoGen for Myeloproliferative Disorders: Likelihood of Approval
Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase I for Myeloproliferative Disorders. According to GlobalData, Phase...
Pivekimab sunirine by ImmunoGen for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
Pivekimab sunirine by ImmunoGen for Myelodysplastic Syndrome: Likelihood of Approval
Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
Pivekimab sunirine by ImmunoGen for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Pivekimab sunirine by ImmunoGen for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Pivekimab sunirine by ImmunoGen for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Pivekimab sunirine by ImmunoGen for Blood Cancer: Likelihood of Approval
Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Blood Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of AbbVie's Pivekimab sunirine?
Pivekimab sunirine is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Refractory Acute Myeloid...